Custom PgUGT29 Protein & Antibody Enable Saponin Biosynthesis Discovery | AtaGenix

Study Context

Platycodon grandiflorus (balloon flower) has been used in traditional medicine for centuries, prized for anti-inflammatory, anti-tumor, and cognitive-enhancing properties. These bioactivities trace back to triterpenoid saponins — particularly Platycodin D (PD) and its glycosylated derivative Platycodin D3 (PD3). But the enzymes responsible for each glycosylation step were largely uncharacterized, blocking efforts to engineer higher saponin yields through metabolic engineering.

A 2025 study published in International Journal of Molecular Sciences (DOI: 10.3390/ijms26104832) by researchers at Anhui University of Chinese Medicine identified 107 UGT genes in the P. grandiflorus genome and pinpointed PgUGT29 as the enzyme catalyzing PD-to-PD3 conversion at the C3 position. Proving this required two things: a functional recombinant enzyme for in vitro activity assays, and a specific antibody to detect the enzyme in plant tissues.

Figure 1. Overview of UGT gene family analysis in P. grandiflorus and the PD-to-PD3 glycosylation pathway. Among 107 identified UGTs, PgUGT29 was confirmed as the enzyme catalyzing C3-glycosylation of Platycodin D using UDP-glucose as the sugar donor.

The Challenge

This project presented a dual challenge that required two different AtaGenix service lines working in parallel. On the protein side, plant-derived UGT enzymes are notoriously difficult to express in E. coli — they frequently form inclusion bodies, and even when solubilized through refolding, many lose catalytic activity. The team needed not just purified protein, but enzymatically active protein that could convert PD to PD3 in an HPLC-detectable assay. They also needed PgUGT72 as a negative control to prove that glycosylation was specific to PgUGT29, not a generic UGT activity.

On the antibody side, detecting PgUGT29 in plant tissue extracts required a polyclonal antibody with high specificity for PgUGT29 over the other 106 UGT family members — a stringent selectivity requirement given the high sequence similarity within the UGT superfamily.

AtaGenix's Approach

AtaGenix delivered an integrated protein + antibody solution:

• Protein Expression: His-tagged PgUGT29 and PgUGT72 were expressed in E. coli BL21(DE3) using IPTG induction (1 mM, 37°C, 4 h). As anticipated, both proteins partitioned primarily into inclusion bodies.
• Refolding & Purification: Inclusion bodies were solubilized in urea, then refolded via stepwise dialysis to restore native conformation. Ni-NTA affinity chromatography yielded >95% purity at 0.21–0.50 mg/mL. Protein identity and integrity were confirmed by SDS-PAGE and Western Blot.
• Antibody Development: AtaGenix designed immunogens targeting PgUGT29-specific epitopes (focusing on the PSPG motif region that differs from other UGT family members) and produced rabbit-derived polyclonal antibodies. Specificity was validated by Western Blot and immunofluorescence — the antibody detected PgUGT29 without cross-reacting with PgUGT72 or other plant UGTs.
• Functional Validation Support: AtaGenix provided HPLC-based enzymatic assay support to confirm that refolded PgUGT29 catalyzed the transfer of glucose from UDP-Glc to PD at the C3 position, producing PD3. PgUGT72 served as the negative control (no PD3 peak detected), confirming reaction specificity.

Results and Impact

The HPLC data provided unambiguous evidence: PgUGT29 converted PD to PD3 in vitro, while PgUGT72 did not. The anti-PgUGT29 antibody confirmed protein expression in P. grandiflorus root tissues, consistent with the known site of saponin accumulation. Together, these results established PgUGT29 as the first characterized C3-glucosyltransferase in the Platycodin D biosynthetic pathway.

For the broader field, this finding opens the door to metabolic engineering: overexpressing PgUGT29 in P. grandiflorus or heterologous hosts could increase PD3 yields for pharmaceutical production, while the antibody provides a tool for monitoring enzyme expression levels during optimization.

Figure 2. HPLC and molecular docking analysis. AtaGenix-produced PgUGT29 catalyzed PD-to-PD3 conversion in vitro (PgUGT72 negative control showed no activity). Molecular docking identified key UDP-Glc binding residues (T145, D392, Q393, N396) within the PSPG motif, providing structural insight into substrate specificity.

This case study is based on a published research collaboration. Results may vary depending on target protein, construct design, and project scope. All proprietary client information is subject to NDA.